Based on the Antibe Therapeutics Inc stock forecast from 0 analysts, the average analyst target price for Antibe Therapeutics Inc is not available over the next 12 months. Antibe Therapeutics Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Antibe Therapeutics Inc is Bearish, which is based on 2 positive signals and 6 negative signals. At the last closing, Antibe Therapeutics Inc’s stock price was USD 0.22. Antibe Therapeutics Inc’s stock price has changed by +0.00% over the past week, +0.00% over the past month and +0.00% over the last year.
No recent analyst target price found for Antibe Therapeutics Inc
No recent average analyst rating found for Antibe Therapeutics Inc
Company Overview Antibe Therapeutics Inc
Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead compound is Otenaproxesul, an NSAID that releases hydrogen sulfide for treating post-operative pain, migraine, acute musculoskeletal pain, dysmenorrhea, gout, and dental pain. In addition, its products comprise ATB-352, which is in preclinical stage for acute pain. The company was incorporated in 2009 and is headquartered in Toronto, Canada. As of March 17, 2025, Antibe Therapeutics Inc. operates as a subsidiary of Taro Pharmaceuticals Inc. Read Less
Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that s...Read More
Frequently Asked Questions About Antibe Therapeutics Inc (ATBPF) Stock
Stock Target Advisor's fundamental analysis for Antibe Therapeutics Inc's stock is Bearish.
Unfortunately we do not have enough data on ATBPF's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on ATBPF's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on ATBPF's stock to indicate if its overvalued.
The last closing price of ATBPF's stock was USD 0.22.
The most recent market capitalization for ATBPF is USD 0.01B.
Unfortunately we do not have enough analyst data on ATBPF's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Antibe Therapeutics Inc's stock.
As per our most recent records Antibe Therapeutics Inc has 11 Employees.
Antibe Therapeutics Inc's registered address is 15 Prince Arthur Avenue, Toronto, ON, Canada, M5R 1B2.
You can get more information about it from Antibe Therapeutics Inc's website at https://www.antibethera.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Antibe Therapeutics Inc (ATBPF) Stock
Stock Target Advisor's fundamental analysis for Antibe Therapeutics Inc's stock is Bearish.
Unfortunately we do not have enough data on ATBPF's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on ATBPF's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on ATBPF's stock to indicate if its overvalued.
The last closing price of ATBPF's stock was USD 0.22.
The most recent market capitalization for ATBPF is USD 0.01B.
Unfortunately we do not have enough analyst data on ATBPF's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Antibe Therapeutics Inc's stock.
As per our most recent records Antibe Therapeutics Inc has 11 Employees.
Antibe Therapeutics Inc's registered address is 15 Prince Arthur Avenue, Toronto, ON, Canada, M5R 1B2.
You can get more information about it from Antibe Therapeutics Inc's website at https://www.antibethera.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ATBPF !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
